Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma [Seeking Alpha]
Arcellx, Inc. (ACLX)
Company Research
Source: Seeking Alpha
Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx's strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million. Anito-cel's Phase 3 trial results are expected by yearend 2024, with a possible BLA submission in 2025, entering a $34.4 billion market. Despite a premium valuation, ACLX's strong pipeline, promising clinical data and strategic partnership with Gilead's Kite justify a "strong-buy" rating. Floaria Bicher/iStock via Getty Images Arcellx, Inc. ( NASDAQ: ACLX ) is a biotechnology company with innovative oncology CAR-T cell therapies. ACLX leverages proprietary platforms, including D-Domain, ddCAR, and ARC-SparX, to enhance the immune system's capabilit
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Arcellx, Inc. (NASDAQ: ACLX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $81.00 price target on the stock.MarketBeat
- Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Arcellx Provides Second Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
ACLX
Earnings
- 8/8/24 - Beat
ACLX
Sec Filings
- 9/17/24 - Form 4
- 9/17/24 - Form 144
- 9/12/24 - Form 4
- ACLX's page on the SEC website